Myasthenia gravis: the role of complement at the neuromuscular junction

James F. Howard(University of North Carolina at Chapel Hill)

Annals of the New York Academy of Sciences

December 21, 2017

10.1111/nyas.13522

Cited by 196

Related Papers

Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data

|Gut|2009|411

Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b/2a study

|The Lancet Neurology|2023|255

Comparative effectiveness of azathioprine and mycophenolate mofetil for myasthenia gravis (PROMISE-MG): a prospective cohort study

|The Lancet Neurology|2024|53

Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

|Neurology|2023|26